Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1040522.RAa6GmIZEpgzWRi1el6gCcbV2oGpkgN8Sdr4cuCaR8PCs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1040522.RAa6GmIZEpgzWRi1el6gCcbV2oGpkgN8Sdr4cuCaR8PCs130_assertion type Assertion NP1040522.RAa6GmIZEpgzWRi1el6gCcbV2oGpkgN8Sdr4cuCaR8PCs130_head.
- NP1040522.RAa6GmIZEpgzWRi1el6gCcbV2oGpkgN8Sdr4cuCaR8PCs130_assertion description "[However, there are subgroups of patients with HCV-2, such as those with advanced fibrosis/cirrhosis, in whom SVR rates are still suboptimal, and highly responsive groups in whom SVR rates reach 95%.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1040522.RAa6GmIZEpgzWRi1el6gCcbV2oGpkgN8Sdr4cuCaR8PCs130_provenance.
- NP1040522.RAa6GmIZEpgzWRi1el6gCcbV2oGpkgN8Sdr4cuCaR8PCs130_assertion evidence source_evidence_literature NP1040522.RAa6GmIZEpgzWRi1el6gCcbV2oGpkgN8Sdr4cuCaR8PCs130_provenance.
- NP1040522.RAa6GmIZEpgzWRi1el6gCcbV2oGpkgN8Sdr4cuCaR8PCs130_assertion SIO_000772 23286844 NP1040522.RAa6GmIZEpgzWRi1el6gCcbV2oGpkgN8Sdr4cuCaR8PCs130_provenance.
- NP1040522.RAa6GmIZEpgzWRi1el6gCcbV2oGpkgN8Sdr4cuCaR8PCs130_assertion wasDerivedFrom befree-2016 NP1040522.RAa6GmIZEpgzWRi1el6gCcbV2oGpkgN8Sdr4cuCaR8PCs130_provenance.
- NP1040522.RAa6GmIZEpgzWRi1el6gCcbV2oGpkgN8Sdr4cuCaR8PCs130_assertion wasGeneratedBy ECO_0000203 NP1040522.RAa6GmIZEpgzWRi1el6gCcbV2oGpkgN8Sdr4cuCaR8PCs130_provenance.